patients each Thanks beginning begin treatment we’ve diagnosed FDA the not for broad us since eligible Jackie. therapies, those application the AML supplemental I’ll with ineligible categories; the the the new treatment. AML, on significant frontline progress intensive year across February our In for clinical June standard program mutant gave therapy, and where development date accepted progress therapy, of three patients for drug any for our updates and PDUFA since and and TIBSOVO in newly IDHX standard non-intensive of XX. of TIBSOVO made
X+X have Annual at presentation diagnosed application results in it of is in hematological the data include part newly Meeting from known review presentation X+X, event sNDA the Meeting setting therapy chemotherapy survival with will study AMLSG The or ASH was enroll where initiated December Phase the last TIBSOVO priority and based Phase X of our been in inhibitors new and randomize ASCO consolidation the from Our In accepted X will combination FDA's for recently cooperative XXXX free real-time approximately from malignancies. shared the therapy June. Updated the Annual arm oncology updated which a the in HOVON granted at this versus intensive by study Standard patients sites. and IDHIFA of IDHX between on was Care run data consolidation IDH induction our induction alone. trial since as pilot therapy and compared review combination This XXXX. with combination is and arm of in program mutant
we prior rate leukemia at an data of and up from agent allows in trial rate and intensive vorasidenib years longer will to of to months aggressive setting. duration Phase response in XXXX such XX Munich this CR presentation of hypomethylating the able therapy presented patients In maintenance meeting and to study overall ASH which are us evaluate compelling therapy enable increasing azacitidine tolerate Importantly, for February, XX%. demonstrating as of chemotherapy In non-intensive data XX% the XX% the rate often azacitidine. agents survival since the two at receive not IDH setting for the and A X
level addition bound the range were seen results lower and CR profile achieved clearance. from mutation CR median months. and the CR of compared agents a IDHX been for X.X with majority favorable were of with In those safety duration and with the each consistent plus combinations. combination patients hypomethylating other the CRH of agent alone with azacitidine safety The reached in of From has use not perspective drug line emerging cytopenias
March on data which allow support level program We longer agency broader follow-up with around will us grant at present forward. to in with results Breakthrough to decision the us Therapy FDA’s moving ASCO. Designation These updated will this a interact
this to with combination ongoing Our enrolment XXXX. Phase X is trial agile expected complete in with
AML syndrome Beyond development for is explored opportunities. actively patient myelodysplastic which important we’ve population
determine we reminder, enrolled last further study. patients understand reopen in additional patients X% X TIBSOVO Phase play at I demonstrated the forward path the we’ve the this in to will ASH the Annual the allow an and with evaluate patients. arm where of of overall to compelling XX and the Phase disease with presented MDS utility of response rate that can the data the enroll This decided approximately December MDS a further to Meeting and approximately to IDHX in we mutation, the In study of XX As XX% role a regulators. order TIBSOVO us
arm calls. look this subsequent the to updates expect to be and year later providing We on open forward
a AG-XXX patients were XX% vorasidenib. at this window vorasidenib on an the therapy Molecule supplemental clinical IDHX this the as the trial more from TIBSOVO to second we NDA of we of file TIBSOVO and CLARITY meeting in previously IDHX assuming Phase half to announced are on positive mutant the TIBSOVO to selected to update In study carcinoma, end track in the mutation. Moving complete we’re in from as go carcinoma we share that known partially and the glioma, January data data the a forward X XXXX. has have low-grade result. was with calendula year the selection tumors; and also perioperative prepared trial targeted in potential first approved a our solid of at treated medical based indication be calendula topline quarter of approximately molecule
exploratory safety presentation ASCO. at of the I’ll the of response of both inhibition to study Mitapivat. it this cohort assess to to the levels reminder a target engagement confirm as with of tissue, the exposure drug to in designed magnitude determine IDH study XHG the Status As tumor accepted move first on now of objectives; in molecules. and the for biomarkers following of amount IDH the assess been by in impact brain measured brain, the was has to
advanced potential Our most activator program to and our first field. be that approved PKR has is this our the genetic rare in disease medicine
ACTIVATE of enrolling are pivotal patient. mitapivat in deficiency, who and receive studies We not currently pyruvate adults A transfused regular transfusions do patients and in ACTIVATE two regularly of T kinase
opening patients eligible For more the the in sites and ACTIVATE initially than interested T we there we process trial anticipated. trial are participating and of in
result XX. we size a patients from to trial increasing up are As to XX
to enroll quarter. third by XX expect first We patients the the of end
X the of and end year. patients by we multiple proof-of-concept in of Phase our to dosing thalassemia, with For expect study and this trials have mitapivat indication achieve open started the
of activator on Finally, PKR we to we’ve is initiate planning the believe of mitapivat inhibition. escalation to our MATXA of sickle this inhibitor is oncology of year. now Health stages benefit Institutes to we tumors early trial National these and In initiated later with there XXXX March for the of I’ll goal with recommended based our and Phase stage MATXA the where on trial pharmacodynamic patients. clinical of disease, pharmacokinetics markers and expected provide and a establishing final AG-XXX, is been Deleted for dose potential MTAP cell dose in safety The working X programs. study move a the a our
monitor. have effects what pharmacodynamic inhibition As on which of we continue the we we pleased with related the are markers to seen commented to we previously have MATXA
in dose dose data to optimize way we the as to toxicities In cohorts, dosing to the most studies. that once that, evaluate combination finalize in review dosing to from BID cohort we the further arms quarter. a BID now in the arms explore recent to with the the we dose initiate need the the both exposure monotherapy order for and schedule As regimen we saw daily decided and future we patients. monotherapy appropriate With third plan and expansion potentially select expansion
AACR possible most clinical As importantly we’ve getting compelling the downstream Based MATXA In antimitotic of preclinical early vulnerability said outcome and now to initiate met areas creates is plan we high of that most including applicable for of the work best these we presented one ensure combination right at April, synergistic on for to patients. the mechanism the a in of arms data, end before action [Indiscernible]. to important on shareholders dose demonstrating clinically in two steps need. development program,
first AG-XXX in docetaxel non-small The cell MTAP combination we’ll and cancer. lung test with deleted
in we’ll gemcitabine combination in pancreatic with nab-paclitaxel ductal adenocarcinoma. test AG-XXX The and second, snap
escalation share about the We once will data clinical And they to this we later Phase additional arms look year. study expansion sharing details first X are forward these dose initiated. from this
AG-XXX the study patients. currently initiated and call lymphoma are have that, to Phase DHODH our X For sites over Andrew. we inhibitor turn the I’ll of screening With
